Exelixis (EXEL) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
27 May, 2026Opening remarks and agenda
Meeting called to order by the President and CEO, with key executives and independent auditors present.
Meeting held virtually, allowing stockholders to participate, submit questions, and vote online.
Agenda and rules of conduct provided in the virtual portal; only proposals in the proxy statement to be voted on.
Notice of meeting confirmed, and only stockholders of record as of March 31, 2026, entitled to vote.
Overview of voting outcomes
Quorum established with 90.16% of shares represented.
All 11 director nominees elected to serve until the next annual meeting in 2027.
Ernst & Young ratified as independent public accounting firm for the current fiscal year.
Amendment to the 2017 Equity Incentive Plan approved, increasing authorized shares by 2 million.
Advisory approval of executive compensation as disclosed in the 2026 proxy statement.
Q&A with stakeholders
No germane questions or comments received from stockholders; Q&A session was foregone.
Latest events from Exelixis
- Transitioning to a multi-franchise model with imminent zanza launch and broad pipeline expansion.EXEL
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Zanza is positioned to become the next-generation TKI leader in oncology, driving future growth.EXEL
Jefferies Global Healthcare Conference 20263 Jun 2026 - Disciplined franchise-building in GU/GI oncology drives innovation, growth, and pan-tumor leadership.EXEL
Bernstein 42nd Annual Strategic Decisions Conference27 May 2026 - Zanzalintinib targets leadership in CRC and RCC with pivotal trials and robust clinical strategy.EXEL
Stifel 2026 Targeted Oncology Virtual Forum20 May 2026 - CABO and zanza drive growth with strong launches, pivotal trials, and robust commercial execution.EXEL
RBC Capital Markets Global Healthcare Conference 202619 May 2026 - Zanzalintinib and CABOMETYX fuel growth as new studies and pipeline assets target solid tumors.EXEL
Barclays 28th Annual Global Healthcare Conference17 May 2026 - Flexible capital deployment supports CABO and zanza growth, with major trials and launches ahead.EXEL
Bank of America Global Healthcare Conference 202612 May 2026 - Q1 2026 saw 10% revenue growth, strong cabozantinib sales, and zanzalintinib NDA progress.EXEL
Q1 20266 May 2026 - Zanzalintinib advances as a next-gen TKI amid strong growth and expanding oncology pipeline.EXEL
TD Cowen 46th Annual Health Care Conference29 Apr 2026